BRAF and melanoma: Several studies have reported that melanoma cells carrying active BRAF mutations are able to increase secretion of immunosuppressive cytokines, lower expression of tumour-associated antigens, and upregulate checkpoints ligands as PD-L1/L2, leading to the suppression of T-cell activities [44,45,46].